Effects of puerarin supplementation on cardiovascular disease risk factors: a randomised, double-blind, placebo-controlled, two-way crossover trial (abridged secondary publication)
MK Kwok1, GM Leung1, L Xu2, HF Tse3, TH Lam1, TH So4, CM Schooling1,5
1 School of Public Health, The University of Hong Kong, Hong Kong SAR, China
2 School of Public Health, Sun Yat-sen University, Guangzhou, China
3 Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong SAR, China
4 Department of Clinical Oncology, School of Clinical Medicine, The University of Hong Kong, Hong Kong SAR, China
5 City University of New York Graduate School of Public Health and Health Policy, New York, NY, United States
- In healthy Chinese men in Hong Kong, short-term (12-week) supplementation with puerarin granules (90.2 mg daily) did not improve cardiovascular disease risk profile including lipid profile, blood pressure, testosterone, inflammation, coagulation, liver function, and renal function.
- Fasting glucose was reduced after puerarin supplementation. Further research is needed to determine whether puerarin can help to improve glycaemic traits.